We are on the move! The content hosted on this website is transitioning. All the information on nuclear medicine and our commitment to leading the development and delivery of radioligand therapies (RLTs) to patients can be found here: https://www.novartis.com/research-and-development/technology-platforms/radioligand-therapy.
Please note that Siemens Healthineers has acquired the Novartis radionuclide molecular imaging business. Learn more
At Novartis, we are making the promise of next-generation medicines a reality today by leading the development of radioligand therapies (RLTs), a novel approach to cancer care. This precision approach aims to improve quality of life and extend people’s lives.
Siemens Healthineers has acquired the Advanced Accelerator Applications Molecular Imaging business for fluorine-18 based positron emission tomography (PET) imaging diagnostics.